[go: up one dir, main page]

FR2806913B1 - Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale - Google Patents

Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale

Info

Publication number
FR2806913B1
FR2806913B1 FR0004120A FR0004120A FR2806913B1 FR 2806913 B1 FR2806913 B1 FR 2806913B1 FR 0004120 A FR0004120 A FR 0004120A FR 0004120 A FR0004120 A FR 0004120A FR 2806913 B1 FR2806913 B1 FR 2806913B1
Authority
FR
France
Prior art keywords
mucosal
adjuvant
pharmaceutical composition
aliphatic quaternary
quaternary ammoniums
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0004120A
Other languages
English (en)
Other versions
FR2806913A1 (fr
Inventor
Hamour Christine Klinguer
Dominique Velin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0004120A priority Critical patent/FR2806913B1/fr
Priority to EP01921451A priority patent/EP1267923A1/fr
Priority to AU48441/01A priority patent/AU4844101A/en
Priority to PCT/FR2001/000984 priority patent/WO2001074387A1/fr
Publication of FR2806913A1 publication Critical patent/FR2806913A1/fr
Application granted granted Critical
Publication of FR2806913B1 publication Critical patent/FR2806913B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0004120A 2000-03-31 2000-03-31 Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale Expired - Fee Related FR2806913B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR0004120A FR2806913B1 (fr) 2000-03-31 2000-03-31 Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale
EP01921451A EP1267923A1 (fr) 2000-03-31 2001-04-02 Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale
AU48441/01A AU4844101A (en) 2000-03-31 2001-04-02 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical compositionadministered by mucosal delivery
PCT/FR2001/000984 WO2001074387A1 (fr) 2000-03-31 2001-04-02 Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0004120A FR2806913B1 (fr) 2000-03-31 2000-03-31 Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale

Publications (2)

Publication Number Publication Date
FR2806913A1 FR2806913A1 (fr) 2001-10-05
FR2806913B1 true FR2806913B1 (fr) 2003-01-31

Family

ID=8848716

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0004120A Expired - Fee Related FR2806913B1 (fr) 2000-03-31 2000-03-31 Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale

Country Status (4)

Country Link
EP (1) EP1267923A1 (fr)
AU (1) AU4844101A (fr)
FR (1) FR2806913B1 (fr)
WO (1) WO2001074387A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
CA2126101A1 (fr) * 1991-12-17 1993-06-24 Robert J. Debs Therapie genique de l'activite de regulation de la conductance transmembranaire dans la fibrose kystique (cftr)
US5951988A (en) * 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
KR19980067138A (ko) * 1997-01-31 1998-10-15 박원훈 유전자 또는 생물학적 활성 약물을 세포내로 효과적으로 전달하는 지방 유제 및 그것의 제조방법
US6271200B1 (en) * 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
AU4537100A (en) * 1999-05-12 2000-12-05 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
WO2000073263A1 (fr) * 1999-05-28 2000-12-07 Vical Incorporated Dimeres de cytofectine et procedes d'utilisation associes
AU773778B2 (en) * 1999-09-08 2004-06-03 Watson Pharmaceuticals, Inc. Using quaternary ammonium salts for transdermal drug delivery
AU1738201A (en) * 1999-10-26 2001-05-08 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Adjuvants for nucleic acid vaccines

Also Published As

Publication number Publication date
FR2806913A1 (fr) 2001-10-05
EP1267923A1 (fr) 2003-01-02
AU4844101A (en) 2001-10-15
WO2001074387A1 (fr) 2001-10-11

Similar Documents

Publication Publication Date Title
EP1383931A4 (fr) Vaccins d'acide nucleique pour la prevention d'infection a flavivirus
FR2802655B1 (fr) Compositions photosensibles comprenant des esters d'oximes comme photoamorceurs
LU92397I2 (fr) Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
EP1263461A4 (fr) Formulations d'adenovirus
ATE321569T1 (de) Kombinierte impfstoffzusammensetzungen
FR2812883B1 (fr) Utilisation d'inhibiteurs d'hppd comme agents de selection dans la transformation de plantes
ID29468A (id) Komposisi farmasi yang stabil dalam bentuk liofil
DZ3177A1 (fr) Copolymère comprenant l'acide isophtalique.
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
AR027890A1 (es) Formulaciones para verter
EP0996719A4 (fr) Nouvelle molecule d'acide nucleique
FR2857263B1 (fr) Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
FR2823892B1 (fr) Borne de stationnement payant pour une pluralite d'emplacements de stationnement
FR2806913B1 (fr) Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale
FR2847818B1 (fr) Composition pharmaceutique a base d'acide hyaluronique
IT1313383B1 (it) Struttura efficiente di integratore a capacita' commutate integrato
EP1037656A4 (fr) Lymphotactine utilisee comme adjuvant
FR2798857B1 (fr) Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
FR2800280B1 (fr) Nouvelle composition vaccinale et utilisation d'agents tensioactifs comme adjuvants d'immunite
EP1449823A4 (fr) Diester d'acide dibasique
FR2781160B1 (fr) Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2818907B1 (fr) Utilisation de la brivudine pour la preparation d'une composition pharmaceutique
EP1397041A4 (fr) Preparations d'acide non-adecadienoique conjugue
FR2792833B1 (fr) Utilisation de l'acide n-anisoyl-gamma-aminobutyrique ou de l'acide p-anisique pour la preparation d'une composition pharmaceutique

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20051130